Edwards Lifesciences Corp.

Allegations that Edwards Lifesciences Corp. and its CEO made materially false and misleading statements and omissions regarding the company's transcatheter aortic valve replacement platform, inflating its stock price.

Edwards Lifesciences Corp. and CEO Bernard J. Zovighian have agreed to a $39 million settlement to resolve a securities class action lawsuit. The lawsuit alleged that the company made false and misleading statements about the growth prospects of its transcatheter aortic valve replacement platform, which allegedly inflated the stock price. Investors who purchased or acquired Edwards Lifesciences Corp. common stock between February 6, 2024, and July 24, 2024, inclusive, and suffered damages may be eligible to file a claim. The claim deadline is December 2, 2026. Proof of purchase and sale, along with supporting documentation, is required.

You may be eligible if you:

• All persons and entities who purchased or otherwise acquired Edwards Lifesciences Corp. common stock between February 6, 2024, and July 24, 2024, inclusive, and suffered damages...

• Basic contact information
• Dates tied to your purchase or account activity
• Proof of purchase or supporting documents

If you do not have every document, you may still be able to file. Many settlements accept claims without receipts.

• File a claim online at the provided link or download and mail the PDF claim form.
• Submit required proof of holdings and transactions, such as broker confirmation slips or account statements.
• The claim deadline is December 2, 2026.